Literature DB >> 21250969

Personal practice: how we manage the risk of bleeding and thrombosis in children and young adults with acute lymphoblastic leukaemia.

Emma Astwood1, Ajay Vora.   

Abstract

Bleeding and thrombosis are not infrequent problems in children receiving treatment for acute lymphoblastic leukaemia (ALL). The exact frequency varies with age, co-morbidity and treatment schedule, but the risk is highest in the first few weeks of treatment when disease and treatment-related haemostatic abnormalities prevail. Recommendations for prevention and management are lacking due to a weak evidence base, resulting in considerable variation in practice. This article describes our personal practice in this area with reference to the available literature on the subject.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21250969     DOI: 10.1111/j.1365-2141.2010.08446.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Hyperfibrinolysis and acquired factor XIII deficiency in newly diagnosed pediatric malignancies.

Authors:  Verena Wiegering; Oliver Andres; Paul G Schlegel; Frank Deinlein; Matthias Eyrich; Alexander Sturm
Journal:  Haematologica       Date:  2013-06-10       Impact factor: 9.941

2.  Supplementation of fibrinogen concentrate in children with severe acquired hypofibrinogenaemia during chemotherapy for acute lymphoblastic leukaemia: our experience.

Authors:  Paola Giordano; Matteo Luciani; Massimo Grassi; Francesco De Leonardis; Valentina Coletti; Nicola Santoro
Journal:  Blood Transfus       Date:  2013-03-05       Impact factor: 3.443

3.  THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents.

Authors:  Jeanette Greiner; Martin Schrappe; Alexander Claviez; Martin Zimmermann; Charlotte Niemeyer; Reinhard Kolb; Wolfgang Eberl; Frank Berthold; Eva Bergsträsser; Astrid Gnekow; Elisabeth Lassay; Peter Vorwerk; Melchior Lauten; Axel Sauerbrey; Johannes Rischewski; Andreas Beilken; Günter Henze; Wolfgang Korte; Anja Möricke
Journal:  Haematologica       Date:  2018-09-27       Impact factor: 9.941

Review 4.  Pediatric Fibrinogen PART II-Overview of Indications for Fibrinogen Use in Critically Ill Children.

Authors:  Gemma Louise Crighton; Elise J Huisman
Journal:  Front Pediatr       Date:  2021-04-21       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.